PCAT6 May Be a Whistler and Checkpoint Target for Precision Therapy in Human Cancers.

Abstract

LncRNAs are involved in the occurrence and progressions of multiple cancers. Emerging evidence has shown that PCAT6, a newly discovered carcinogenic lncRNA, is abnormally elevated in various human malignant tumors. Until now, PCAT6 has been found to sponge various miRNAs to activate the signaling pathways, which further affects tumor cell proliferation, migration, invasion, cycle, apoptosis, radioresistance, and chemoresistance. Moreover, PCAT6 has been shown to exert biological functions beyond ceRNAs. In this review, we summarize the biological characteristics of PCAT6 in a variety of human malignancies and describe the biological mechanisms by which PCAT6 can facilitate tumor progression. Finally, we discuss its diagnostic and prognostic values and clinical applications in various human malignancies.

• Authors: Feng Jiang, Qiaoyi Lv, Cexun Hu, Zhanghui Li, Haojie Wu, Shujun Gao, Hui Wang, Yangjing Zhao, Qixiang Shao
• Journal: Cancers (Cancers (Basel)) Vol. 13 Issue 23 (Dec 03 2021) ISSN: 2072-6694 [Print] Switzerland
• PMID: 34885209 (Publication Type: Journal Article, Review)